Epithalon — Clinical Reference

**⚠ Educational reference only — not medical advice.** This article is for research and educational reference. Always consult your own physician before considering any peptide protocol. See the full Disclaimer at the end of this article. ## Introduction Epithalon (epitalon, AEDG) is a synthetic tetrapeptide developed by Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology — a short-peptide analogue of epithalamin, the active fraction of the pineal gland. Investigational; no FDA-approved indication. ## Mechanism of Action The proposed mechanism centers on transcriptional regulation. Peptide-DNA binding studies and in-vitro work suggest Epithalon increases telomerase activity, extends replicative lifespan in somatic cells, and modulates melatonin synthesis via pineal-axis effects. ## Research Indications Russian-language clinical literature reports use in age-related morbidity, cardiovascular endpoints, and visual function in retinitis pigmentosa cohorts. Western peer-reviewed data are limited. Best regarded as an investigational longevity-research peptide. ## Reconstitution Typical 10 mg lyophilized vial: add **5 mL of bacteriostatic water**, swirl gently. Final concentration **2000 mcg/mL (2 mg/mL)** — each 0.25 mL (25 units on a U-100 insulin syringe) delivers 5 mg. ## Dosing Protocol (research literature) Khavinson-school protocols typically use **5–10 mg subcutaneously once daily** in short pulse courses — **10 consecutive days, repeated every 6 months** — rather than continuous dosing. Some protocols use intranasal administration with equivalent total daily dose. Continuous daily dosing is not the published model. ## Administration Subcutaneous injection into abdominal fat, rotating sites within each pulse course. Intranasal administration is also documented in published protocols. ## Storage & Handling Lyophilized: refrigerate (2–8°C). Reconstituted: refrigerate; stable approximately **14–21 days** — most pulse courses use a single reconstituted vial across the 10-day course. Protect from light. ## Side Effects Mild in available reports: injection-site reactions, occasional headache. Long-term safety data are sparse and largely confined to a single research program. ## Contraindications Pregnancy, lactation, and active malignancy given telomerase-modulating activity. Caution in any condition where unregulated cellular proliferation would be undesirable. ## Monitoring Baseline CBC and comprehensive metabolic panel; an age-related morbidity instrument appropriate to the indication. Re-evaluate at 3 and 6 months. Telomere-length assays remain non-standardized and are not recommended as routine monitoring. ## Disclaimer **This article is for informational and research-reference purposes only.** Nothing in this document constitutes medical advice, a prescription, or a recommendation from a physician. The reconstitution, dosing, and protocol information above reflects ranges commonly cited in published research and clinician-directed protocols — it is provided as reference material only, not as instructions, an endorsement of off-label use, or a substitute for individualized medical evaluation. **Customers should do their own research and consult their own physician** before considering any peptide protocol. Whether a given compound is appropriate for an individual — and at what dose, for what duration, and alongside what monitoring — is a decision that only a licensed clinician with knowledge of that individual's medical history, current medications, and conditions can make. The platform and the author make no claim that any compound described here is safe, effective, or appropriate for any particular person or purpose, and accept no responsibility for outcomes arising from self-directed use of the information.